Conjugated monoclonal antibodies and their role against cancer
Tallennettuna:
| Tekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | artículo de revisión |
| Julkaisupäivä: | 2024 |
| Kuvaus: | Cancer involves the proliferation of abnormal cells at an accelerated rate, which can have metastatic and invasive qualities. This illness is a significant public health problem worldwide. Usual treatments are surgery, radiotherapy, and chemotherapy. The drawback of these strategies is their adverse effects, which is why more specific options have been sought. Conjugated monoclonal antibodies have been manufactured to achieve this goal. Their structure comprises a monoclonal antibody, a cytotoxic agent or payload, and a linker, which holds the first two components together. Thanks to this technology, novel medications have yielded better results than traditional therapies. Through these findings, 11 drugs in this therapeutic category are being marketed worldwide. As a complement, significant advances in treating this pathology have led to continued research. In the short term, more conjugated monoclonal antibodies are expected to be approved by health authorities such as the United States Food and Drug Administration and the European Medicines Agency. |
| Maa: | Kérwá |
| Organisaatio: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| Kieli: | Inglés |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/103085 |
| Linkit: | https://hdl.handle.net/10669/103085 https://doi.org/10.30574/wjbphs.2024.19.3.0532 |
| Sanahaku: | cancer biological drug monoclonal antibody linker payload antibodies |